The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival impact of switching to different topoisomerase I or II inhibitors-based regimens (topo-I or topo-II) in extensive-disease small cell lung cancer (ED-SCLC): supplemental analysis from JCOG0509.
 
Shogo Nomura
Employment - Asahi Kasei (I)
 
Shigeki Umemura
Honoraria - Boehringer Ingelheim
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); MSD (Inst)
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - AstraZeneca; Bayer; Lilly; Novartis; Takeda
 
Tomohiro Shinozaki
No Relationships to Disclose
 
Taro Shibata
No Relationships to Disclose
 
Kenichi Nakamura
Honoraria - Daiichi Sankyo; Lilly; Taiho Pharmaceutical; Takeda
 
Miyako Satouchi
Speakers' Bureau - AstraZeneca; Chugai Pharma; Lilly; Nippon Boehringer Ingelheim; Novartis; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Yuichiro Ohe
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Hisamitsu Pharmaceutical; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche Pharma AG; Sanofi; Taiho Pharmaceutical; Yakult Pharmaceutical
Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Lilly; Novartis; Ono Pharmaceutical; Roche Pharma AG
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Haruhiko Fukuda
Honoraria - Chugai Pharma; Nippon Boehringer Ingelheim; Novartis; Taiho Pharmaceutical